Tirzepatide is a synthetic research peptide studied for its activity as a dual GIP/GLP-1 receptor agonist — engaging two distinct incretin receptor pathways within a single molecule. Developed originally by Eli Lilly, it sits between single-receptor compounds like semaglutide and the newer triple-agonist retatrutide, making it a common middle point of comparison in incretin research. Helix Bio supplies Tirzepatide as a lyophilized powder intended strictly for laboratory and preclinical research, manufactured to a high-purity standard and backed by third-party verification. It is not intended for human consumption, diagnostic use, or any therapeutic application, and it is a separate product from FDA-approved branded medications.
HPLC certified
Independent analysis
Highest standard
Full traceability
Tirzepatide is studied as a dual incretin receptor agonist — a peptide engineered to engage both the GIP receptor and the GLP-1 receptor, rather than the GLP-1 receptor alone. That distinguishes it from earlier single-target compounds like semaglutide and liraglutide, and it's part of why researchers use it as a comparison point when characterizing what a second (or third, in retatrutide's case) receptor target adds mechanistically to incretin pharmacology.
Helix Bio's Tirzepatide is supplied as a lyophilized (freeze-dried) powder — a synthetic peptide manufactured under controlled laboratory conditions. Lyophilization extends shelf stability prior to reconstitution, which is useful for labs running studies over an extended timeline rather than using a full vial at once.
This product exists to support in vitro and preclinical laboratory research only. It's manufactured, labeled, and sold for research use only (RUO) — not for human or veterinary use, not for diagnostic procedures, and not for compounding. It's intended for researchers studying dual incretin receptor pharmacology, GIP/GLP-1 signaling, or metabolic research models.
Tirzepatide occupies a useful middle position in incretin research — it adds a second receptor target on top of the GLP-1-only compounds, without the added complexity of a third. That makes it a natural comparator whether your study design is benchmarking against semaglutide on one side or retatrutide on the other. Helix Bio manufactures its Tirzepatide domestically, backs every batch with purity testing, and issues documentation so researchers can evaluate what they're working with before it reaches the bench. If your protocol calls for a well-characterized dual-agonist peptide with a clear paper trail, that's what this listing is built around.
This product is not intended for individual consumers seeking to use it outside a research setting, and it is not a substitute for any FDA-approved medication.
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Cyclic peptides resist protease degradation and reach undruggable targets. Learn how peptide cyclization works and why stability improves. Explore the research.
How continuous flow, automation, enzymatic routes and AI are changing peptide synthesis technology, and what it means for research peptide purity and supply.
AI now designs peptides from scratch. How AlphaFold 3, RFdiffusion and protein language models reshaped peptide discovery in 2026 — research use only.
